← 產業報告目錄
Urea Cycle Disorder Treatment Market, By Treatment Type (Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, and Others (Low Protein Diet, Carglumic acid, etc.)), By Enzyme Deficiency Type (OTC Ornithine Transcarbamylase, AS Argininosuccinate Synthetase (citrullinemia), AG Arginase, AL Argininosuccinate Lyase, CPS1 Carbamoyl Phosphate Synthase, and NAGS N-acetylglutamate Synthase), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
出版商 Coherent Market Insights出版日期 2026-07-08頁數 258報告編號 CMR-7aac3f7b53
授權報價
| Single User Price | $4,500 USD |
| Site License Price | $7,000 USD |
| Enterprisewide Price (Global Site License) | $10,000 USD |
報告摘要
The global urea cycle disorders treatment market includes various therapies such as amino acid supplements, sodium phenylbutyrate, glycerol phenylbutyrate, sodium benzoate, low protein diet, carglumic acid, etc. for the treatment of the inherited disorder such as urea cycle disorders, which affects various enzymes taking part in the urea cycle pathway in the human system. The urea cycle disorders are classified according to the deficiencies observed in different enzymes of the urea cycle such as OTC – ornithine transcarbamylase, ASD – argininosuccinic acid synthetase (citrullinemia), AG – Arginase, ALD – argininosuccinase acid lyase (argininosuccinic aciduria), CPS – carbamoyl phosphate synthetase, and NAGS – N-acetylglutamate synthetase.
Market Dynamics
Market players are focused on adopting different business strategies such as mergers and acquisitions in order to expand their offerings in the market.
For instance, in February 2017, Mead Johnson Nutrition Company (MJN) announced its merger with Reckitt Benckiser Group plc (RB). Mead Johnson, now a division of RB, added its globally-recognized brands, including Enfa and Nutramigen, which are used in dietary management of urea cycle disorder, to RB’s consumer health portfolio, thus strengthening its position globally.
Moreover, For Instance, In October 2017, Lucane Pharma SA was acquired by the Eurocept Pharmaceuticals, a company developing, distributing, and marketing of medicinal products in therapeutic areas such as anesthesia, oncology, immunology, and neurology. This acquisition has aided Eurocept Pharmaceuticals to invest in research and development of medicines for rare metabolic diseases such as urea cycle disorders.
Furthermore, Key players focused on inorganic strategies such as distribution agreements in order to strengthen their presence in the market.
For Instance, In 2016, Horizon Pharma plc and Swedish Orphan Biovitrum AB (publ) (Sobi), a biotechnological company in Sweden, announced the distribution agreement for the distribution of Ravicti in European countries including the U.K,. Germany, Italy, France, and Spain.
Key features of the study
• This report provides in-depth analysis of the global urea cycle disorders treatment market, provides market size (US$ Mn) and compound annual growth rate (CAGR) (%) for the forecast period (2026–2033)
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, country outlook, and competitive strategies adopted by the leading players.
• It profiles leading players in the global urea cycle disorders treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and future plans
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions with respect to their future market expansion and marketing tactics
• The global urea cycle disorders treatment market report caters to various stakeholders in this industry, including investors, product developers and manufacturers, distributors, healthcare organizations, research institutes, new entrants, and financial analysts
• Stakeholders would greatly benefit in decision-making through various strategy matrices used in analyzing the global urea cycle disorders treatment market
Market Segmentation
• By Treatment Type (Revenue, USD Mn, 2021-2033)
o Amino Acid Supplements
o Sodium Phenylbutyrate
o Glycerol Phenylbutyrate
o Sodium Benzoate
o Others (Low Protein Diet, Carglumic acid, etc.)
• By Enzyme Deficiency Type (Revenue, USD Mn, 2021-2033)
o OTC – Ornithine Transcarbamylase
o AS – Argininosuccinate Synthetase (citrullinemia)
o AG – Arginase
o AL – Argininosuccinate Lyase
o CPS1 – Carbamoyl Phosphate Synthase
o NAGS – N-acetylglutamate Synthase
• By Route of Administration (Revenue, USD Mn, 2021-2033)
o Oral
o Injectable
• By Distribution Channel (Revenue, USD Mn, 2021-2033)
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• By Region (Revenue, USD Mn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o Bausch Health Companies, Inc.
o Recordati Rare Diseases Inc.
o Lucane Pharma SA
o Acer Therapeutics
o Ultragenyx Pharmaceutical Inc.
o Aeglea BioTherapeutics
o Arcturus Therapeutics Holdings Inc.
o Orpharma Pty Ltd.
o Selecta Biosciences, Inc.
o Abbott Laboratories
o NESTLE S.A.
o DANONE S.A.
o Mead Johnson & Company, LLC
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Treatment Type
Market Snapshot, By Enzyme Deficiency Type
Market Snapshot, By Route of Administration
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Drivers
o Restraints
o Opportunities
o Impact Analysis
o Key Developments
o Treatment Approaches
o Novel Therapies Under Development for the Treatment of UCD
o Mergers, Collaborations, Acquisitions & Agreements
o Pipeline Analysis
o Regulatory Scenario
o PEST Analysis
o Product Approvals
o Market Trends
o Epidemiology
o Therapeutics Overview
o Brand Analysis
o Reimbursement Scenario
o Prescription Overview
4. Global Urea Cycle Disorders Treatment Market, By Treatment Type, 2021-2033 (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022-2033
Segment Trends
o Amino Acid Supplements
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Sodium Phenylbutyrate
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Glycerol Phenylbutyrate
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Sodium Benzoate
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Others (Low Protein Diet, Carglumic acid, etc.)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Urea Cycle Disorders Treatment Market, By Enzyme Deficiency Type, 2021-2033 (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022-2033
Segment Trends
o OTC – Ornithine Transcarbamylase
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o AS – Argininosuccinate Synthetase (citrullinemia)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o AG – Arginase
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o AL – Argininosuccinate Lyase
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o CPS1 – Carbamoyl Phosphate Synthase
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o NAGS – N-acetylglutamate Synthase
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Urea Cycle Disorders Treatment Market, By Route of Administration, 2021-2033 (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022-2033
Segment Trends
o Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Injectable
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Urea Cycle Disorders Treatment Market, By Distribution Channel, 2021-2033 (USD Mn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022-2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
8. Global Urea Cycle Disorders Treatment Market, By Region, 2021-2033 (USD Mn)
o Introduction
Market Share Analysis, By Country, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Countries, 2022-2033
North America
o Introduction
Market Size and Forecast, By Treatment Type, 2021-2033 (USD Mn)
Market Size and Forecast, By Enzyme Deficiency Type, 2021-2033 (USD Mn)
Market Size and Forecast, By Route of Administration, 2021-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Mn)
Market Size and Forecast, By Country, 2021-2033 (USD Mn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, By Treatment Type, 2021-2033 (USD Mn)
Market Size and Forecast, By Enzyme Deficiency Type, 2021-2033 (USD Mn)
Market Size and Forecast, By Route of Administration, 2021-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Mn)
Market Size and Forecast, By Country, 2021-2033 (USD Mn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, By Treatment Type, 2021-2033 (USD Mn)
Market Size and Forecast, By Enzyme Deficiency Type, 2021-2033 (USD Mn)
Market Size and Forecast, By Route of Administration, 2021-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Mn)
Market Size and Forecast, By Country, 2021-2033 (USD Mn)
o Germany
o U.K.
o France
o Italy
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, By Treatment Type, 2021-2033 (USD Mn)
Market Size and Forecast, By Enzyme Deficiency Type, 2021-2033 (USD Mn)
Market Size and Forecast, By Route of Administration, 2021-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Mn)
Market Size and Forecast, By Country, 2021-2033 (USD Mn)
o China
o India
o Japan
o Australia
o South Korea
o ASEAN
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, By Treatment Type, 2021-2033 (USD Mn)
Market Size and Forecast, By Enzyme Deficiency Type, 2021-2033 (USD Mn)
Market Size and Forecast, By Route of Administration, 2021-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Mn)
Market Size and Forecast, By Country, 2021-2033 (USD Mn)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, By Treatment Type, 2021-2033 (USD Mn)
Market Size and Forecast, By Enzyme Deficiency Type, 2021-2033 (USD Mn)
Market Size and Forecast, By Route of Administration, 2021-2033 (USD Mn)
Market Size and Forecast, By Distribution Channel, 2021-2033 (USD Mn)
Market Size and Forecast, By Country/Region, 2021-2033 (USD Mn)
o South Africa
o Central Africa
o North Africa
9. Competitive Landscape
o Company Profiles
Bausch Health Companies, Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Recordati Rare Diseases Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Lucane Pharma SA
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Acer Therapeutics
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Ultragenyx Pharmaceutical Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Aeglea BioTherapeutics
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Arcturus Therapeutics Holdings Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Orpharma Pty Ltd.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Selecta Biosciences, Inc.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Abbott Laboratories
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
NESTLE S.A.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
DANONE S.A.
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
Mead Johnson & Company, LLC
o Company Overview
o Product Portfolio
o Financial Overview
o Key Highlights
o Market Strategies
10. Section
o References
o Research Methodology
o About Us
圖表清單 List of Tables & Figures
NA
NA
提及公司
o Bausch Health CompaniesInc.o Recordati Rare Diseases Inc.o Lucane Pharma SAo Acer Therapeuticso Ultragenyx Pharmaceutical Inc.o Aeglea BioTherapeuticso Arcturus Therapeutics Holdings Inc.o Orpharma Pty Ltd.o Selecta BiosciencesInc.o Abbott Laboratorieso NESTLE S.A.o DANONE S.A.o Mead Johnson & CompanyLLC
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們